Cargando…
In vivo pharmacology and anti-tumour evaluation of the tyrphostin tyrosine kinase inhibitor RG13022.
Amplification and increased expression of many growth factor receptors, including the epidermal growth factor receptor (EGFR), has been observed in human tumours. One therapeutic strategy for overcoming EGF autocrine control of tumour growth is inhibition of EGFR protein tyrosine kinase (PTK). A ser...
Autores principales: | McLeod, H. L., Brunton, V. G., Eckardt, N., Lear, M. J., Robins, D. J., Workman, P., Graham, M. A. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1996
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2077212/ https://www.ncbi.nlm.nih.gov/pubmed/8956783 |
Ejemplares similares
-
The inhibition of EGF-dependent proliferation of keratinocytes by tyrphostin tyrosine kinase blockers
Publicado: (1991) -
Inhibition of pancreatic cancer cell growth in vitro by the tyrphostin group of tyrosine kinase inhibitors.
por: Gillespie, J., et al.
Publicado: (1993) -
Acute stimulation of glycolytic flux in cultured primary astrocytes by the tyrosine kinase inhibitor tyrphostin 23
por: Blumrich, Eva-Maria, et al.
Publicado: (2015) -
Tyrphostin AG17 inhibits adipocyte differentiation in vivo and in vitro
por: Camacho, Alberto, et al.
Publicado: (2018) -
Tyrphostin AG 1296 induces glioblastoma cell apoptosis in vitro and in vivo
por: LI, HONGWEI, et al.
Publicado: (2015)